

**UCC Library and UCC researchers have made this item openly available.
Please [let us know](#) how this has helped you. Thanks!**

Title	Deprescribing in older people: why it matters in routine clinical practice
Author(s)	O'Mahony, Denis; Curtin, Denis
Publication date	2018
Original citation	O'Mahony, D. and Curtin, D. (2018) 'Deprescribing in older people: why it matters in routine clinical practice', Polish Archives of Internal Medicine, 128(4), pp. 197-199. doi: 10.20452/pamw.4255
Type of publication	Other
Link to publisher's version	http://pamw.pl/en/issue/article/29708955 http://dx.doi.org/10.20452/pamw.4255 Access to the full text of the published version may require a subscription.
Rights	This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. https://creativecommons.org/licenses/by-nc-sa/4.0/
Item downloaded from	http://hdl.handle.net/10468/6539

Downloaded on 2020-10-30T07:16:17Z

Deprescribing in older people: why it matters in routine clinical practice

Denis O'Mahony, Denis Curtin

Department of Medicine (Geriatrics), University College Cork and Department of Geriatric Medicine, Cork University Hospital, Cork, Ireland

Polypharmacy in older people presents a real threat to the health and welfare of older people globally, because of the close cause-and-effect relationship with inappropriate prescribing and adverse drug reactions (ADRs) and adverse drug events (ADEs). Given the phenomenon of population aging both in developed and developing countries, it is clear that the heightened risk of ADRs and ADEs from polypharmacy represents a major global public health problem.

Polypharmacy is traditionally defined (somewhat arbitrarily) as the intake of 5 or more daily drugs, with major polypharmacy usually meaning consumption of 10 or more daily drugs. The cause of polypharmacy in old age is clearly multimorbid illness, that is, more chronic medical conditions leading to more drugs being prescribed.¹ The difficulty is that the risk of ADRs or ADEs rises in parallel with increasing medication, so that the risk of an older person experiencing drug adversity of one kind or another when taking 10 daily drugs is about 100%. It is therefore in older patients' best interest to restrict the number of daily drugs they are prescribed. The difficulty for prescribers is that there is no agreed "safe limit" for the number of daily drugs. Most prescribers appreciate that it is very easy to add more drugs to the prescription of older persons with multimorbidity; it is much more difficult to remove drugs (or "deprescribe") from their prescription list.

In the present issue of this journal, Bień and Bień-Barkowska² retrospectively examine the changes in the prescriptions of 301 older people from admission to discharge from a specialist geriatric medicine unit in one hospital in Białystok, Poland. The mean age of the patients was 82.4 years and two-thirds were female, as expected for a geriatric hospital cohort such as this. They found a significant reduction in the number of drugs prescribed per patient from admission (average 7.53 drugs per patient) to discharge (average 6.25 drugs per patient) and that 57% of the patients experienced

a reduction in medication. The patients who experienced the most deprescribing were those who had ADRs, recent falls, and diabetic patients with episodes of hypoglycemia. From a wide range of predictive factors, the number of drugs on admission, the number of comorbid conditions, age, solitary living status, and incident ADRs were the factors that in a multiple logistic regression model accounted for the significant deprescribing in these patients. Low body mass index also had a positive influence: the lower the BMI, the greater the degree of deprescribing by the attending physicians. The authors conclude that in-patient specialist geriatric assessment achieved significant deprescribing. Because of the retrospective nature of the study, it was not possible to determine what (if any) effect the deprescribing had on patients' cognition or physical function or quality of life.

The findings of Bień and Bień-Barkowska² may not be surprising. Specialist geriatricians are trained to examine multimorbid older patients' medication lists carefully, given that polypharmacy engenders inappropriate prescribing and ADRs or ADEs.³ Deprescribing in specialist geriatric medical units arises through careful medication review, which has always been an integral part of comprehensive geriatric assessment, the cornerstone of specialist geriatric medical practice. Careful medication review and optimization in the context of comprehensive geriatric assessment (or "geriatric evaluation and management" in the study by Bień and Bień-Barkowska) in turn depends on specialist training and wide knowledge of drug-related problems in old age as well as the various and often nonspecific manifestations of ADRs and ADEs in older people. Geriatricians will also be keenly aware of "prescribing cascades", that is inappropriate prescribing of new medication for presenting symptoms in multimorbid older people that are misinterpreted as symptoms of new medical conditions in these patients. For example, an older person with

Correspondence to:

Prof. Denis O'Mahony, MD, FRCPI,
Department of Medicine (Geriatrics),
University College Cork, Ireland &
Consultant Physician, Cork University
Hospital, Wilton, Cork, Ireland,
phone: +353 21 4922 396,
email: denis.omahony@ucc.ie

Received: April 3, 2018.

Accepted: April 3, 2018.

Published online: April 27, 2018.

Conflict of interest: DO is the
inventor and principal developer
of STOPP/START criteria.

Pol Arch Intern Med. 2018;

128 (4): 197-199

doi:10.20452/pamw.4255

Copyright by Medycyna Praktyczna,

Kraków 2018

dementia who receives a neuroleptic antipsychotic for night-time agitation develops parkinsonism. The patient is referred to another physician regarding the parkinsonism and is subsequently commenced on levodopa. The patient becomes hypotensive on levodopa and subsequently suffers a fracture injury due to a syncopal fall relating to inappropriately prescribed levodopa.

Several explicit potentially inappropriate medication (PIM) lists exist in the literature that were designed specifically for the growing older person population. The most commonly cited among the explicit PIM lists are Beers criteria (now in its 5th iteration⁴) and STOPP criteria (now in its 2nd iteration⁵). There are also several implicit PIM lists designed for the geriatric population, most notably ACOVE criteria and the Medication Appropriateness Index. Although implicit PIM criteria sets are undoubtedly useful as research tools, none has entered routine clinical practice as a deprescribing tool, probably because they are too time-consuming to deploy. In contrast, Beers criteria and STOPP criteria are now used in several countries as routine medication review tools. Beers criteria have been endorsed by the American Geriatrics Society for several years. STOPP criteria are recommended in the recent UK National Institute for Clinical Excellence guidelines for structured medication review in older people with polypharmacy as a practical means of deprescribing (<https://www.nice.org.uk/guidance/ng5>).

Despite the multiplicity of explicit deprescribing criteria sets, few randomized clinical trials (RCTs) exist in which deprescribing criteria have been used as an intervention and compared with standard pharmaceutical care. Only STOPP criteria have been tested by an RCT; currently, there are 3 RCTs involving STOPP in the hospital setting and 1 RCT in a large nursing home facility. All 4 RCTs are single-center and none was double-blinded. Two of these RCTs took place in our center; the primary outcomes in these RCTs were medication appropriateness and incident ADRs, respectively.^{6,7} The total average number of drugs per patient was not significantly reduced in the intervention groups compared with controls in these 2 trials, most probably because whatever deprescribing was achieved through application of STOPP criteria was likely counterbalanced by addition of new medications through application of START criteria. In the RCT reported by Frankenthal et al,⁸ undertaken in 359 frail nursing home residents in Israel, application of STOPP/START criteria did achieve significant reduction in the number of daily drugs in the intervention cohort (mean [SD], 8.1 [3.2]) compared with the control cohort (mean [SD], 9.0 [3.3]). Although the proportion of intervention patients with PIMs at hospital discharge was significantly less than controls in the RCT by Dalleur et al,⁹ the impact of STOPP/START criteria on the average number of daily medications in the intervention cohort was not documented.

The challenge now facing researchers in this area is how to implement PIM criteria in the routine clinical care of older patients with polypharmacy. Researchers generally agree that meeting this challenge depends on sufficiently robust software to apply PIM criteria and to present the relevant PIM criteria that apply to individual patients to their physicians accurately and quickly. To this end, 2 important RCTs have recently been funded by the European Commission: SENATOR¹⁰ and OPERAM.¹¹ The software interventions tested in these trials are based primarily on STOPP/START version 2 criteria.⁵ The SENATOR trial has been completed this year and OPERAM is expected to finish randomization later in 2018. SENATOR has randomized over 1500 patients to standard pharmaceutical or once-off software-driven application of STOPP/START criteria as well as drug-drug and drug-disease interactions. OPERAM is expected to randomize over 1800 patients in a cluster randomized design to standard pharmaceutical care or single-time point application of STOPP/START criteria using a different software engine. These multicenter trials will determine whether software-driven deprescribing reduces ADRs (SENATOR) and drug-related unscheduled hospitalizations (OPERAM).

Are there any practical guidelines to help physicians deprescribe drugs effectively and safely, specifically in very frail older multimorbid patients with poor survival prognosis who represent a very important and growing population of older people globally? In these patients, the focus of pharmacotherapy should be on symptom relief as distinct from long-term primary or secondary disease prevention. In this context, drugs that would be generally appropriate (eg, statins, calcium supplements) become potentially futile. Scott et al¹² have recently proposed a protocol for assessing individual medications in older people burdened by polypharmacy. A follow-up small-scale open-label study of 50 older multimorbid patients (mean age, 82.5 years) by the same group showed that a median number of 10 medications at hospital admission could be reduced to a median of 7 medications at discharge, with less than 2% of deprescribed drugs needing to be represcribed at follow-up (median, 78 days).¹³ A small-scale RCT involving 47 older intervention patients and 48 control patients in 4 nursing homes in Western Australia using the same deprescribing algorithm showed a mean (SD) reduction of 1.9 (4.1) drugs per patient compared with a slight mean (SD) increase of +0.1 (3.5) drugs in the control group at 1-year follow-up.¹⁴ In contrast to the implicit deprescribing algorithm of Scott et al¹² are the recently published 27 explicit deprescribing STOPPFrail criteria.¹⁵ An RCT involving STOPPFrail criteria as the intervention compared with standard pharmaceutical care in frail, multimorbid older people with poor survival prognosis is being conducted in our center. While the results of all these clinical trials are awaited, physicians should nevertheless

seek to deprescribe medication in frail multimorbid older people.

ACKNOWLEDGMENTS The publication was supported by projects funded by the European Union, SENATOR (grant no. 305930) and OPERAM (grant no. 634238-2).

NOTE The opinions expressed by the author are not necessarily those of the journal editors, Polish Society of Internal Medicine, or publisher.

OPEN ACCESS This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (<http://creativecommons.org/licenses/by-nc-sa/4.0/>), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. For commercial use, please contact the journal office at pamw@mp.pl.

REFERENCES

- 1 O'Mahony D. Optimizing pharmacotherapy for older patients. In: Michel JP, Beattie BL, Martin FC, Walston JD, eds. *Oxford Textbook of Geriatric Medicine* 3rd edition. Oxford, United Kingdom: Oxford University Press; 2017: 183-188.
- 2 Bień B, Bień-Barkowska K. Prescribing or deprescribing in older persons: what are the real-life concerns in geriatric practice? *Pol Arch Intern Med.* 2018; 128: 200-208.
- 3 Anathhanam S, Powis RA, Cracknell AL, Robson J. Impact of prescribed medications on patient safety in older people. *Ther Adv Drug Saf.* 2012; 3: 165-174. [↗](#)
- 4 By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc.* 2015; 63: 2227-2246.
- 5 O'Mahony D, O'Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing.* 2015; 44: 213-218. [↗](#)
- 6 Gallagher PF, O'Connor MN, O'Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. *Clin Pharmacol Ther.* 2011; 89: 845-854. [↗](#)
- 7 O'Connor MN, O'Sullivan D, Gallagher PF, et al. Prevention of hospital-acquired adverse drug reactions in older people using screening tool of older persons' prescriptions and screening tool to alert to right treatment criteria: a cluster randomized controlled trial. *J Am Geriatr Soc.* 2016; 64: 1558-1566. [↗](#)
- 8 Frankenthal D, Lerman Y, Kalendaryev E, Lerman Y. Intervention with the screening tool of older persons potentially inappropriate prescriptions/screening tool to alert doctors to right treatment criteria in elderly residents of a chronic geriatric facility: a randomized clinical trial. *J Am Geriatr Soc.* 2014; 62: 1658-1665. [↗](#)
- 9 Dalleur O, Boland B, Losseau C, et al. Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: a randomised controlled study. *Drugs Aging.* 2014; 31: 291-298. [↗](#)
- 10 SENATOR. <https://www.senator-project.eu/>. Accessed March 31, 2018.
- 11 OPERAM. <http://www.operam-2020.eu/>. Accessed March 31, 2018.
- 12 Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. *JAMA Intern Med.* 2015; 175: 827-834. [↗](#)
- 13 McKean M, Pillans P, Scott IA. A medication review and deprescribing method for hospitalised older patients receiving multiple medications. *Intern Med J.* 2016; 46: 35-42. [↗](#)
- 14 Potter K, Flicker L, Page A, Etherton-Beer C. Deprescribing in frail older people: a randomised controlled trial. *PLoS One.* 2016; 11: e0149984.
- 15 Lavan AH, Gallagher P, Parsons C, O'Mahony D. STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy): consensus validation. *Age Ageing.* 2017; 46: 600-607. [↗](#)